摘要
目的观察阿那曲唑对绝经后乳腺癌术前新辅助治疗的临床应用效果。方法选择符合标准的患者在外科手术前12周开始分别接受阿那曲唑1mg1mg.d-1及他莫昔芬20mg.d-1,于治疗前、治疗后每4周及外科手术前分别对所有患者记录基线测量(二维、使用测量器)和乳腺B超测量(二维)结果并采集血标本检测血雌二醇水平及各项生化指标。结果阿那曲唑组可评价疗效31例,CR0例,PR11例,总有效率35.5%,SD17例,PD3例,占9.8%。他莫昔芬组可评价疗效27例,CR0例,PR8例,总有效率29.6%,SD14例,PD5例,占18.5%。所有患者辅助治疗结束后均可予行改良根治术。E2的平均抑制率两组分别为77.6%和76.6%。所有病例药物耐受均较好,不良反应轻微。结论阿那曲唑用于绝经后乳腺癌术前新辅助治疗疗效明显,不良反应轻微、耐受良好;且疗效和耐受性均稍好于他莫昔芬。
OBJECTIVE To observe the clinic effect of neoadjuvant treatment of postmenopausal breast cancer with anastrozole. METHODS the patients were treated with anastrozole or tamoxifen from Preoperative 12 week to operation.The diameter of tumor were measured by sliding caliper and ultrasound on Preoperative 12 week , 8 week, 4 week and the Preoperative 1 day. And the estrogen receptor level was identified at the same time. RESULTS Among 31 samples treated with anastrozole, no one get complete response, 11 sample get partial response, 17 sample were stable and 3 sample were progressing. Among 27 samples treated with tamoxifen, no one get complete response, 8 sample get partial response, 14 sample were stable and 5 sample were progressing. The adverse effect were insignificant on all patient.CONCLUSION The neoadjuvant treatment of postmenopausal breast cancer with anastrozole would be a better choice.
出处
《海峡药学》
2010年第4期71-73,共3页
Strait Pharmaceutical Journal
关键词
阿那曲唑
乳腺癌
内分泌治疗
Anastrozole
Breast neoplasms
Endoerine therapy
